The adjusted net income and diluted earnings per share amounts in the table below are non-GAAP financial measures and should not be considered a substitute for any performance measure determined in accordance with U.S. GAAP. Additional information regarding the use of these non-GAAP financial measures is included in Talecris' Form 10-Q filed with the SEC on April 27, 2011, which is available on SEC's website at www.sec.gov and Talecris' website at http://ir.talecris.com.Diluted EarningsPre-TaxIncome TaxPer(in thousands, except per share amounts)AmountBenefitNet IncomeCommon ShareThree Months Ended March 31, 2011U.S. GAAP$
.43Grifols merger-related expenses4,118(1,552)2,5660.02Interest on PCA judgment740(289)451-Excluding specific items$
.45Three Months Ended March 31, 2010U.S. GAAP$
.35EBITDA, Adjusted EBITDA, and Consolidated Cash FlowTalecris believes that a meaningful analysis of its operating performance is enhanced by the use of EBITDA, adjusted EBITDA as defined in Talecris' revolving credit facility and Consolidated Cash Flow as defined in its 7.75% Notes.
EBITDA, adjusted EBITDA, and Consolidated Cash Flow are financial measures that are not defined by accounting principles generally accepted in the U.S. (U.S. GAAP). A non-GAAP financial measure is a numerical measure of a company's financial performance that (i) excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in a comparable measure calculated and presented in accordance wi
|SOURCE Talecris Biotherapeutics Holdings Corp.|
Copyright©2010 PR Newswire.
All rights reserved